CASI Pharmaceuticals Inc. (CASI, Financial) experienced a significant decline in its stock price, dropping by 5.01%. The stock is currently trading at $5.66 per share with a trading volume of 65,713 shares and a turnover rate of 0.43%, showing a price volatility of 8.05%.
Recent financial reports for CASI reveal that the company generated $3.98 million in revenue, suffered a net loss of $6.97 million, and an earnings per share of -$0.52. The gross profit was $2.07 million, with the price-to-earnings ratio calculated at -2.80. Among the analysts covering the stock, 100% have recommended buying, with no hold or sell recommendations.
In the broader biotechnology sector, there was an overall decline of 0.73%. Notable gainers in the sector included 60 Degrees Pharmaceuticals Inc, Lixte Biotechnology Holdings Inc, and Conduit Pharmaceuticals Inc. Meanwhile, Sonnet Biotherapeutics Holdings, Inc. and Elevai Labs, Inc. exhibited significant activity, with turnover rates of 3367.65% and 503.82%, respectively. Volatility was prominent in stocks like Sonnet Biotherapeutics Holdings, Inc., Cardio Diagnostics Holdings Inc., and 60 Degrees Pharmaceuticals Inc.
CASI Pharmaceuticals is a biopharmaceutical company focused on the commercialization of innovative therapies and drug products, with a substantial portion of its revenue derived from the sale of EVOMELA, used in conditioning treatment before autologous stem cell transplantation in multiple myeloma patients. The company's operations span across the United States, Canada, China, and other global regions.
